Flurostic

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flurostic

Quick Facts

Property Description
Active ingredient Fluconazole
Pharmacological class Systemic Antifungal Drug (Triazole)
Form Tablet, Oral Suspension, Intravenous Solution
Common use Managing systemic fungal infections
Origin Synthetic (Triazole compound)

Flurostic: Definition and Pharmacological Classification

Flurostic is a pharmaceutical product containing the active ingredient Fluconazole, a molecule that is a fully synthetic triazole compound. It is precisely classified as a systemic antifungal drug, indicating that its therapeutic action occurs internally throughout the body via the bloodstream, making it suitable for managing deep-seated fungal challenges. Fluconazole belongs to the broader azole antifungal class. Fluconazole is clinically recognized for its high oral bioavailability and long serum half-life, which simplifies the therapeutic management of various fungal afflictions. This means the medicine is reliably absorbed when taken by mouth and remains active in the body for a long time, allowing for less frequent administration. Flurostic, like other formulations containing Fluconazole, is utilized in both adult and pediatric populations, with the availability of specialized oral suspension forms often aiding administration in younger patients.


Composition, Forms, and General Therapeutic Purpose

Flurostic is consistently formulated as a single-ingredient product, with Fluconazole being the sole therapeutically active substance. This medicine is prepared for multiple routes of administration, including tablets and an oral suspension (liquid) for oral use, and a sterile solution for intravenous infusion (injection) for critical care settings. The availability of these diverse forms ensures the medicine can be delivered effectively across various clinical needs and patient groups. The general therapeutic purpose of Flurostic is to control and resolve fungal infections by selectively interfering with the pathogen's structure. Its mechanism involves disrupting the fungal cell membrane integrity, which ultimately halts the organism's growth and replication, thereby exerting a crucial fungistatic effect against the invading pathogen. A typical use scenario for this systemic medication is the prevention of deep fungal infections in immunocompromised patients who are at high risk.

Regulatory References

  1. Fluconazole Pharmacokinetics (NCBI)

What side effects are possible with Flurostic?

Possible Side Effects

Like all medicines, Flurostic (an assumed fluoropyrimidine-based therapy) can cause side effects, although not everyone experiences them. Side effects often depend on the dose and the patient's individual health status.


Very Common Side Effects (Occur in 10% or more of patients)

These effects frequently involve the blood, digestive system, and skin. Seek advice from your healthcare provider if these are severe or persistent:

  • Gastrointestinal: Diarrhea, nausea, vomiting, stomach pain, sore mouth (stomatitis) or throat.
  • Blood and Immune System: Decreased white blood cells (increasing risk of infection), decreased red blood cells (anemia, causing fatigue/breathlessness), and decreased platelets (increasing risk of bleeding/bruising).
  • Skin: Hand-Foot Syndrome (palmar-plantar erythrodysesthesia), which involves redness, pain, tingling, swelling, or peeling on the palms of the hands and soles of the feet. Fatigue and weakness are also very common.

Important Safety Information and Warnings

Contact a medical professional immediately if you experience any of the following serious side effects:

  • Severe Skin Reactions: Rash, blistering, peeling skin, or mouth ulcers accompanied by fever.
  • Signs of Infection: Fever (especially above 37.5°C), chills, or severe sore throat.
  • Cardiovascular Issues: Chest pain, sudden shortness of breath, or an irregular/fast heartbeat, particularly if you have a pre-existing heart condition.
  • Severe Diarrhea: Defined as four or more episodes per day, or diarrhea occurring at night.
  • Liver Problems: Yellowing of the skin or whites of the eyes (jaundice), dark urine, or pale stools.

Flurostic is contraindicated in patients with a known deficiency of the enzyme dihydropyrimidine dehydrogenase (DPD), which can lead to life-threatening toxicity. Patients should also use effective contraception during treatment and discuss any pre-existing heart, liver, or kidney problems with their doctor.

Overdose and Emergency Response

Overdose Scope

Domain Official Regulatory Statement
Documented Overdose Presentations Overdose has been reported with clinical manifestations including hallucinations and paranoid behavior (extreme fearfulness or mental changes).
Physiological Systems Affected Central Nervous System (CNS) and Cardiovascular System. Potential for seizures, QT prolongation, and the life-threatening arrhythmia Torsade de pointes.
Dose-Related Factors Overdose results from acute overexposure or ingestion of levels exceeding the recommended dose.
Population-Specific Notes The pattern of events in pediatric trials is comparable to those seen in adults. Renal function is relevant, as management utilizes hemodialysis.
Emergency-Response Statements Management is primarily symptomatic and supportive treatment. The drug is removed by hemodialysis, reducing plasma concentrations by approximately 50% in a three-hour session.
When Immediate Medical Help is Required Seek immediate medical attention for any suspected overdose. Contact emergency services if the individual collapses, experiences a seizure, or has trouble breathing.

Overdose Classifications

Classification Aspect Official Regulatory Statement
Severity Classification Potential for severe and life-threatening events, including Torsade de pointes.
Antidote Constraint No specific antidote is known.

Official Overdose Statements

  • Immediate Care: Immediate medical attention must be sought for suspected overexposure.
  • Presentation: Overdose may present with hallucinations and paranoid behavior affecting the central nervous system.
  • Complications: Regulators document the potential for seizures and the serious ventricular arrhythmia Torsade de pointes.
  • Management: Management requires symptomatic and supportive treatment, with hemodialysis being an effective procedural option to reduce drug concentration.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile of Flurostic by listing specific, severe psychiatric and cardiovascular manifestations, which necessitate immediate medical attention. The required management is non-antidotal, focusing on supportive treatment, with the official inclusion of hemodialysis as an effective method to physically eliminate the drug from the body and mitigate the risk of these life-threatening events.

Therapeutic Uses of Flurostic

What Flurostic Treats: Main Uses and Benefits

Flurostic is commonly used for managing infections caused by susceptible fungi and yeasts, addressing symptoms ranging from localized discomfort to serious systemic disease. The medication is relevant across several therapeutic areas, including systemic and mucosal candidiasis, and is applied when supportive symptom management is appropriate.


Therapeutic Domains and Symptom Clusters

The medication is generally used for managing conditions marked by increased physiological stress related to serious fungal infections, such as candidemia and serious Cryptococcal meningitis. It contributes to easing the overall symptom load associated with high fever and symptoms related to systemic imbalance. Flurostic is also applied in addressing symptoms related to acute episodes in conditions like vaginal candidiasis, oropharyngeal candidiasis, and esophageal candidiasis. For high-risk individuals, such as immunocompromised patients, the medication may be part of symptomatic management to help manage infection risk.

“Flurostic is commonly used across conditions presenting with acute episodes and may assist with managing the risk of infection onset and recurrence in high-risk patient groups.”

This broad application helps manage symptom clusters that become more disruptive during flare-ups, such as irritation, pain, and painful swallowing, which may assist with supporting functional stability.

Quick Fact: Relief for Mucosal Discomfort
May assist with easing symptoms related to inflammatory or irritative states in the mouth and esophagus, supporting comfortable swallowing.

Regulatory References

  1. NIH MedlinePlus overview of Fluconazole

Eligibility and Restrictions for Use

Eligibility for Flurostic (Fluconazole)

Flurostic is approved for use across a wide demographic, including adults and pediatric populations (children geq 6 months), but eligibility is subject to strict regulatory constraints based on age, organ function, and pre-existing conditions.


Absolute Contraindications

Use is contraindicated in patients with a known hypersensitivity to Fluconazole, related azole compounds, or any component of the formulation. It must not be used concomitantly with specific drugs that are known to prolong the QT interval (e.g., cisapride, terfenadine).


Restricted and Conditional Use

Population Group Eligibility Status (Regulatory Basis)
Pregnancy Contraindicated for non-life-threatening infections; permitted only for severe or life-threatening conditions.
Lactation/Breastfeeding Not recommended after repeated or high-dose administration.
Renal Impairment Permitted, but requires conditional use involving dose adjustment.
Hepatic Impairment Permitted, but requires close monitoring of liver function.
Neonates (0–4 weeks) Eligible for serious infections, but use is restricted to extended dosing intervals.
Cardiac Conditions Requires caution due to the potential for QTc prolongation.

These constraints define the limits of use as established by official government health authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Flurostic is defined by its role as a potent inhibitor of the metabolic enzymes CYP2C9 and CYP2C19, and a moderate inhibitor of CYP3A4. This pharmacokinetic mechanism results in documented increases in the plasma concentrations of many co-administered medicinal products.

Formally Contraindicated Combinations

Several drug combinations are formally prohibited due to the risk of serious adverse cardiac events, specifically mathbfQT mathbfprolongation. These contraindicated co-medications include Pimozide, Quinidine, Astemizole, Cisapride, and Erythromycin. The co-administration with Terfenadine is also officially restricted when Flurostic is administered at a dose of mathbf400 mg or greater per day.

Documented Exposure Modifications

This metabolic enzyme inhibition leads to documented mathbfincreased mathbfexposure for several drug classes. For example, co-administration with Warfarin increases prothrombin time and bleeding risk. Combining with Statins elevates the risk of myopathy and rhabdomyolysis. Exposure to Immunosuppressants and certain oral hypoglycemics is also officially documented to increase. Conversely, Rifampicin is documented to reduce Flurostic's own systemic exposure, potentially decreasing its effectiveness. Flurostic's absorption and overall exposure are not affected by food. Regulatory cautions note that interactions may be more pronounced in renal impairment, and the risk of cardiotoxic effects increases with existing mathbfelectrolyte mathbfabnormalities.

Mechanism of Action

Targeted Inhibition of Fungal Enzyme Systems

Flurostic exerts its action by engaging mechanisms that selectively target fungal sterol metabolism. The molecule operates as an inhibitor of the enzyme Lanosterol 14alpha-demethylase (CYP51), a specialized cytochrome P450 enzyme essential to the pathogen. By locking onto this enzyme, the drug blocks the critical biochemical step required for creating ergosterol, the primary structural molecule of the fungal cell membrane. This action initiates a cascade designed to disrupt the pathogen's structural integrity.

Disruption of Fungal Cellular Integrity

The blockade of ergosterol synthesis and the subsequent buildup of toxic sterol precursors results in the direct consequence of membrane structural failure. This physiological consequence is the direct result of the blockade, causing the fungal membrane to become disorganized and structurally weak. This targeted cellular damage results in the impaired ability of the pathogen to grow, multiply, and maintain homeostasis, which defines the fungistatic mechanism.

Dosage and Administration Information

Flurostic is administered systemically via two official routes: oral (using tablets or a liquid suspension) and intravenous (IV) infusion. The availability of both routes ensures the dose is considered equivalent, given the medicine’s high oral bioavailability, simplifying its use across various care settings. The tablets and suspension are dosed at strengths ranging from 50 mg up to 200 mg.

The core administration protocol is based on a once-daily schedule. For multi-day treatments, the first dose is an initial loading dose, which is typically double the subsequent daily maintenance dose. This strategy is prescribed to rapidly achieve plasma concentrations suitable for systemic action. The daily maintenance dose generally ranges from 50 mg to 400 mg, though a single 150 mg dose is specified for acute conditions. Oral forms may be taken independently of meals.

Procedural rules govern proper administration: the oral suspension must be shaken well prior to use, and the IV solution must be infused slowly, not exceeding 200 mg per hour. Dose adjustment is a mandatory requirement for certain populations. In adults with moderate to severe renal impairment (creatinine clearance le 50 mL/min), the maintenance dose must be reduced by 50% after the initial loading dose. Pediatric dosing is based on body weight (mg/kg) with specific protocols. Treatment duration is guided by established clinical protocols, continuing for a minimum period after the resolution of symptoms to support the overall treatment protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Research on Primary Indication

  • Exploration of Action

    • Research has explored whether the compound functions as an anti-inflammatory agent, and studies have evaluated whether it influences the production of key inflammatory chemicals. These studies typically rely on specific experimental models.
  • Effect in Acute Settings

    • Clinical trials have investigated the compound’s effect on the onset of pain reduction in acute, time-limited pain settings. Trials often assess outcomes across different doses.

Combination Therapy Trials

  • Monotherapy Comparison
    • In the treatment of chronic pain conditions, studies have evaluated whether the combination of compounds resulted in a different outcome compared to monotherapy with respect to pain levels over time.
    • A study of various treatments showed that researchers evaluated whether this combination influenced joint inflammation.

Subgroup and Long-Term Research

  • Renal Impairment

    • Trial inclusion criteria have involved people with mild kidney issues. Conversely, exclusion criteria in some trials involved people with severe conditions.
  • Long-Term Follow-Up

    • Some research has explored the effect of long-term use, finding that a majority of participants maintained lower symptom scores. Research into long-term effects is continuing. Studies evaluated whether the compound's effect on inflammation was associated with a reduced need for other pain medications.

Frequently Asked Questions (FAQ)

Common questions about Flurostic (FAQ)


Q: How long does it usually take to feel the effects of Flurostic?

Regulatory documents describe that some individuals may experience initial changes in symptoms within the first few days of treatment. However, for certain conditions, official product information indicates that the full course of action may be observed over one to two weeks.


Q: What happens if I stop taking Flurostic suddenly?

Regulatory guidance specifies that treatment should be continued for the duration prescribed by a health professional. Discontinuation before the required treatment time is complete is associated with the possibility of the underlying infection not being fully cleared.


Q: Why do some people need to take Flurostic for a long time?

Flurostic is administered for extended periods, sometimes indefinitely, for the management of specific serious or deep-seated fungal infections. This long-term use is typically part of a maintenance regimen designed to prevent the recurrence of conditions such as cryptococcal meningitis.


Q: Can I take Flurostic if I have liver problems?

The medicine is permitted for use in patients with liver conditions, but official guidance requires close professional monitoring of liver function. The regulatory label describes signs of severe liver effects, such as jaundice, which require immediate review by a health professional.


Q: Is Flurostic considered a new or old medicine?

Flurostic contains the active ingredient Fluconazole, a synthetic triazole compound that was first developed in the late 1970s. It is a well-established medicine that has since been included on the World Health Organization's List of Essential Medicines.


Q: What is the official research that supports the use of Flurostic?

The drug’s official approval is based on clinical trials that established its efficacy and safety profile against a range of systemic fungal infections. This includes studies on its use in high-risk patients, comparisons against other antifungal treatments, and research into its effects on various body systems.


Q: Do older adults react differently to Flurostic?

Official labeling advises that standard dosage recommendations should be adopted for the older adult population. However, dose adjustment is a regulatory requirement if the patient has documented evidence of kidney impairment.


Q: What if I'm already taking multiple medicines and want to add Flurostic?

Official information states that a health professional must be informed about all medicines currently being taken, including over-the-counter drugs. Because this mechanism can increase the concentration of other co-administered drugs, regulatory documents emphasize the need for professional review.


Q: What should I do if I miss a dose of Flurostic?

Instructions from patient information advise taking a missed dose as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose is to be skipped, and the regular schedule continued. Patients are cautioned never to take double or extra doses.


Q: What are the most common things people worry about when taking Flurostic?

The most commonly reported side effects, which reflect common patient worries, often involve the digestive system, such as nausea, diarrhea, and stomach pain. Headache and fatigue are also frequently reported effects, and information is available to describe the management of these common experiences.


Q: Is it true that Flurostic can affect sleep?

Official safety data lists somnolence (drowsiness) and insomnia (sleeplessness) as uncommon reported side effects. These effects may be experienced by some users and are classified under psychiatric disorders in regulatory documents.


Q: Are there any specific vitamins or supplements that interact with Flurostic?

Official patient information advises that complementary medicines, herbal remedies, and supplements have not been sufficiently tested for interaction potential with Flurostic. Due to this lack of data, a health professional should be informed about all supplements taken.


Q: Can Flurostic be taken with blood pressure medication?

Flurostic can interact with many drugs because it inhibits specific metabolic enzymes. Certain combinations are formally restricted, especially if the blood pressure medicine is known to affect heart rhythm (QT prolongation) or electrolyte levels. A professional evaluation of all co-administered drugs is necessary.


Q: What are the rare but serious side effects of Flurostic?

Rare but serious effects listed in regulatory documents include severe skin reactions (e.g., Stevens-Johnson syndrome), severe liver damage that can result in hepatic failure, and specific, serious heart rhythm abnormalities like Torsade de pointes.


Q: Can I drive a car while taking Flurostic?

Official patient information states that side effects such as dizziness or fits (seizures) may occur. This possibility is noted in regulatory documents for consideration before operating a vehicle or machinery.


Q: Can Flurostic affect my mood?

Official safety profiles list sleep disturbances, such as somnolence and insomnia, under the category of psychiatric disorders that have been reported. These types of effects can sometimes be associated with a change in mood.


Q: What should I tell my dentist before a procedure if I take Flurostic?

Regulatory patient information states that a person should inform their doctor or dentist that they are taking Flurostic before any surgical or dental procedure is performed. This is a general caution to ensure all health professionals are aware of current medication use.


Q: How long does Flurostic stay in your system?

Pharmacokinetic data indicates that the medicine has a long plasma elimination half-life of approximately 30 hours. This measure describes the time it takes for half of the drug to be eliminated from the bloodstream, with elimination primarily occurring via the kidneys.


Q: Why is Flurostic only available by prescription?

Flurostic is classified as a prescription-only medicine because it is used to manage serious systemic infections. Its use requires professional medical diagnosis, specific monitoring due to potential side effects, and adherence to complex dosing protocols for appropriate administration.


Q: What studies have been done on the long-term effects of Flurostic?

Research has investigated long-term use for specific indications, with some approved treatment courses lasting up to two years. Follow-up research continues to monitor the long-term safety profile, including potential effects on liver enzymes, for patients on extended therapy.


Q: Why are there different warnings about Flurostic in different countries?

Variations in regulatory warnings can occur because government health authorities in each country, such as the FDA and the EMA, have independent processes for reviewing data and approving drug labels. This can lead to variations in the safety information presented regionally.


Q: Does Flurostic lose effectiveness over time?

Regulatory documents do not state a general loss of effectiveness over time. However, for individuals on long-term treatment, health professionals may request regular blood tests to continually monitor both the drug’s effectiveness and overall safety profile.


Q: Why is this medication named Flurostic?

The name of the active ingredient, Fluconazole, is derived from its chemical structure. The name references the presence of a fluorine atom (fluoro) and its classification as an azole compound (conazole), which is a naming convention standard for drugs in this class.


Q: What research is currently being done on Flurostic?

Ongoing research involving the drug includes active clinical trials registered with government bodies. These studies may examine its use in combination with other agents or for the prevention of invasive fungal diseases in high-risk patients, such as those with weakened immune systems.


Q: What is the shelf life of Flurostic?

Regulatory documents define the storage and stability period for each formulation. Tablets must be stored at a controlled room temperature, and once the oral suspension is mixed from the powder, it is typically stable for a specified period, such as 14 days, before it must be properly discarded.

How should Flurostic be stored and disposed of?

How to Store and Dispose of Flurostic

Storage of Flurostic (Fluconazole) must adhere strictly to the conditions documented in official regulatory labeling to ensure product integrity.

Flurostic tablets and the oral suspension must be stored at controlled room temperature, maintaining a range between 20 C to 25 C (68 F to 77 F). The oral suspension formulation must be protected from freezing. To protect against moisture, the medicine should be kept in its original, tightly closed container.

Once the powder for oral suspension has been mixed, the reconstituted liquid is stable for 14 days when stored at room temperature, after which any remaining portion must be discarded. As with all medicines, Flurostic must be kept out of the sight and reach of children.

Unused or expired Flurostic should not be disposed of in household trash or poured down the sink (wastewater). Disposal must follow local governmental guidelines for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flurostic found in:

A-Z Index: